Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Mar 15;25(6):1699-1701.
doi: 10.1158/1078-0432.CCR-18-3401. Epub 2019 Jan 4.

TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?

Affiliations
Comment

TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?

Richard J Rebello et al. Clin Cancer Res. .

Abstract

Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al., p. 1766.

PubMed Disclaimer

Comment on

  • TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
    De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY. De Laere B, et al. Clin Cancer Res. 2019 Mar 15;25(6):1766-1773. doi: 10.1158/1078-0432.CCR-18-1943. Epub 2018 Sep 12. Clin Cancer Res. 2019. PMID: 30209161 Free PMC article. Clinical Trial.

LinkOut - more resources